Mr. Richard Muruve reports

GRANT OF OPTIONS TO DIRECTORS AND OFFICERS

Arch Biopartners Inc. has granted a total of 350,000 stock options to directors and officers pursuant to the company's stock option plan and the requirements of the TSX Venture Exchange.

The grant of 350,000 stock options to the directors and officers represents remuneration for serving on the board and managing the company's affairs for the annual period ending April 1, 2024.

Each of these stock options is exercisable into one common share of the company at a price of $1.50 for a period of 10 years, effective Dec. 15, 2023, and will be subject to all necessary regulatory approvals.

About Arch Biopartners Inc.

Arch Biopartners is a late-stage clinical trial company focused on preventing inflammation and acute organ injury. The company is developing new drug candidates that inhibit inflammation in the lungs, kidneys and liver via the dipeptidase-1 (DPEP-1) pathway and are relevant for common injuries and diseases where organ inflammation is an unmet problem.

We seek Safe Harbor.